{"id":250,"date":"2025-05-21T10:00:00","date_gmt":"2025-05-21T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=250"},"modified":"2025-09-09T10:19:20","modified_gmt":"2025-09-09T10:19:20","slug":"china-fic-drug-onradivir","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/250.html","title":{"rendered":"[China FIC Drug] Influenza\u00a0A\u00a0virus\u00a0RNA\u00a0Polymerase PB2 Inhibitor First in Class Drug Onradivir Approved by China NMPA in 2025"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Drug Name:  Onradivir&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Drug Modality: Small Molecule<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Drug Target:  <em>&nbsp;<\/em>Influenza&nbsp;A&nbsp;virus&nbsp;RNA&nbsp;Polymerase PB2 Inhibitor<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Developed By\uff1aGuangdong Raynovent Biotech (subsidiary of Guangdong Zhongsheng Pharmaceutical)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Approved Date:  2025-05 by China NMPA<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Indication: Influenza&nbsp;A<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dosage Form and Strength:  Tablets, 200 mg<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Product  Code: ZSP1273<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name: \u6602\u62c9\u5730\u97e6<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drug Name: Onradivir&nbsp; Drug Modality: Small Molecule Drug Target: &nbsp;Influenza&nbsp;A&nbsp;virus&nbsp;RNA&nbsp;Polymerase PB2 Inhibitor Developed By\uff1aGuangdong Raynovent Biotech &hellip; <a title=\"[China FIC Drug] Influenza\u00a0A\u00a0virus\u00a0RNA\u00a0Polymerase PB2 Inhibitor First in Class Drug Onradivir Approved by China NMPA in 2025\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/250.html\"><span class=\"screen-reader-text\">[China FIC Drug] Influenza\u00a0A\u00a0virus\u00a0RNA\u00a0Polymerase PB2 Inhibitor First in Class Drug Onradivir Approved by China NMPA in 2025<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-250","post","type-post","status-publish","format-standard","hentry","category-china-fic-drug"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=250"}],"version-history":[{"count":4,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/250\/revisions"}],"predecessor-version":[{"id":279,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/250\/revisions\/279"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}